

## CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide

10 January 2023 – Luxembourg >


CordenPharma is pleased to announce the signing of a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.

The manufacturing agreement will potentially cover a value of ca. USD 1 billion, depending on actual production over the term of the agreement, and will support the launch of an innovative peptide. The companies have agreed not to disclose additional details and respect customer confidentiality.

Dr Michael Quirnbach, CEO & President of CordenPharma, commented: “We are very excited about the trust our customer has placed in CordenPharma, and are pleased to continue supporting the commercial manufacturing of this innovative peptide at our CordenPharma Colorado (US) site, which is perfectly equipped for producing these types of complex molecules.

As part of our commitment, we plan to further expand both our large and medium-scale peptide manufacturing capacity at our Colorado and Frankfurt sites, making CordenPharma the leading peptide manufacturing CDMO with full drug product integration, possible via our aseptic fill and finish capabilities in CordenPharma Caponago.”

In parallel, CordenPharma is pursuing a large investment program across its global facility network to expand capacities and technologies in key areas such as Peptides, Lipids, and Injectables, with an overall planned investment of > €200M in 2023.



[Photo by CordenPharma] Commercial Peptide Manufacturing at CordenPharma Colorado (US).

## About CordenPharma

CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.

With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).

The CordenPharma Group is comprised of 12 facilities across Europe and North America. In the 2022 financial year, the organization generated sales of 870 million Euros and had over 3,000 employees.

Please visit [cordenpharma.com](https://www.cordenpharma.com) for more information.

---

### **CordenPharma Media Contacts**

North America: [abby.thompson@cordenpharma.com](mailto:abby.thompson@cordenpharma.com) | Europe & Asia: [eva.schaub@cordenpharma.com](mailto:eva.schaub@cordenpharma.com)